<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51869">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01801930</url>
  </required_header>
  <id_info>
    <org_study_id>293-12-001</org_study_id>
    <nct_id>NCT01801930</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer</brief_title>
  <official_title>A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability of OCV-C02 in Patients With Advanced or Relapsed
      Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of dose limiting toxicity (DLT) will be evaluated in cohorts of six patients
      by starting OCV-C02 administration at dose level 1 (OCV-103 and OCV-104 at 0.3 mg each),
      increasing the dose to dose level 2 (at 1 mg each), and then up to dose level 3 (at 3 mg
      each). Once-weekly administration will be repeated four times in each treatment cycle, and
      the incidence of DLT from Day 1 to Day 29 will be evaluated.

      At the end of Cycle 1, patients who wish to continue OCV-C02 treatment and have provided
      their written consent will be permitted to continue participation in the trial using the
      same dosing schedule for each subsequent cycle as that for Cycle 1.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>1 Month (29Day)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Common Terminology Criteria for Adverse Events (CTCAE), ver. 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>September 2014</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Common Terminology Criteria for Adverse Events (CTCAE), ver. 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>September 2014</time_frame>
    <safety_issue>No</safety_issue>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune-response</measure>
    <time_frame>29 days, September 2014</time_frame>
    <safety_issue>No</safety_issue>
    <description>DTH reactions，CTL Measurement，Blood Regulatory T Cell Measurement</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCV-103 and OCV-104</intervention_name>
    <description>0.3 mg of each</description>
    <arm_group_label>Dose level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCV-103 and OCV-104</intervention_name>
    <description>1 mg of each</description>
    <arm_group_label>Dose level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCV-103 and OCV-104</intervention_name>
    <description>3 mg of each</description>
    <arm_group_label>Dose level 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have human leukocyte antigen (HLA)-A*24:02

          -  Patients who have histologically-confirmed colorectal cancer (adenocarcinoma)

          -  Patients with advanced or relapsed colorectal cancer who are refractory or intolerant
             to standard chemotherapy

          -  Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of
             0 to 1 at the time of enrollment in the trial.

        Exclusion Criteria:

          -  Patients who are HIV antibody test positive

          -  Patients with an active infection

          -  Patients who have or are suspected to have CNS metastasis of colon cancer (such as
             metastatis of the brain)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoji Imaoka, Mr</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunto-gun</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 9, 2013</lastchanged_date>
  <firstreceived_date>February 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OCV-C02</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Antigen specific cancer immunotherapeutic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
